NeuroOne Inc., a Minnetonka, Minnesota-based platform technology company focused on developing advanced neuromonitoring and neuromodulating products, raised $1.2m in seed funding.
Backers included FundRx Inc., an early stage healthcare venture capital firm.
The company intends to use the funds to accelerate its lead product, a neurodiagnostic solution for the treatment of epilepsy.
Led by Dave Rosa, CEO, NeuroOne provides comprehensive neuromodulation cEEG monitoring and treatment solutions for patients suffering from epilepsy and other nerve related disorders. The company, which leverages core technology in partnership with the Mayo Clinic and the University of Wisconsin, is currently pursuing a near-term FDA approval for its lead product through the 510(k) submission process.
FinSMEs
14/03/2017